Substance / Medication

Atorvastatin

Overview

Active Ingredient
atorvastatin
RxNorm CUI
83367

Indications

Atorvastatin calcium tablets is indicated: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinica

Labeler: Umedica Laboratories USA Inc.Updated: 2026-01-30T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

5.3 [see Warnings and Precautions ()] Acute liver failure or decompensated cirrhosis 6.2 [see Adverse Reactions ()]. Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium tablets. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Steven

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

177 trials linked to this intervention

177
Total Trials
24
Recruiting
35
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis.
Sayehmiri Kourosh, Shohani Masoumeh, Qavam SamiraMis et al. · Life Sci · 2025
PMID: 40132725Meta-Analysis
Atorvastatin before percutaneous coronary intervention: A systematic review and meta-analysis.
García-Campa Mariano, Flores-Ramírez Ramiro, Rojo-Garza Sabrina et al. · PLoS One · 2024
PMID: 38165842Meta-AnalysisFull text (PMC)
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis.
Singh Harmanjit, Kaur Sangambir, Kaushal Parul et al. · Expert Rev Clin Pharmacol · 2024
PMID: 39587804Meta-Analysis
Efficacy and Safety of Atorvastatin for Chronic Subdural Hematoma: An Updated Systematic Review and Meta-Analysis.
Monteiro Gabriel de Almeida, Queiroz Thomas Silva de, Gonçalves Ocílio Ribeiro et al. · World Neurosurg · 2024
PMID: 38759787Meta-Analysis
[Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis].
Villegas-Quintero Víctor Eder, Rivas-Ruíz Rodolfo, García-Rivero Alexis Alejandro et al. · Rev Med Inst Mex Seguro Soc · 2023
PMID: 37934798Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Atorvastatin (substance)
SNOMED CT
373444002
UMLS CUI
C0286651
RxNorm CUI
83367
Labeler
Umedica Laboratories USA Inc.

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
177
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.